N

Noile-Immune Biotech Inc
TSE:4893

Watchlist Manager
Noile-Immune Biotech Inc
TSE:4893
Watchlist
Price: 156 JPY -2.5% Market Closed
Market Cap: 6.8B JPY
Have any thoughts about
Noile-Immune Biotech Inc?
Write Note
Noile-Immune Biotech Inc
/
Balance Sheet
/
Other Liabilities

Noile-Immune Biotech Inc
Other Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Noile-Immune Biotech Inc
Other Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
N
Noile-Immune Biotech Inc
TSE:4893
Other Liabilities
¥5.2m
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Other Liabilities
¥13.7B
CAGR 3-Years
23%
CAGR 5-Years
37%
CAGR 10-Years
53%
PeptiDream Inc
TSE:4587
Other Liabilities
¥475.8m
CAGR 3-Years
15%
CAGR 5-Years
26%
CAGR 10-Years
N/A
Takara Bio Inc
TSE:4974
Other Liabilities
¥2.4B
CAGR 3-Years
3%
CAGR 5-Years
10%
CAGR 10-Years
12%
Pharma Foods International Co Ltd
TSE:2929
Other Liabilities
¥581m
CAGR 3-Years
1%
CAGR 5-Years
67%
CAGR 10-Years
59%
C
Cuorips Inc
TSE:4894
Other Liabilities
¥28.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Noile-Immune Biotech Inc
Glance View

Market Cap
6.8B JPY
Industry
Biotechnology

Noile-Immune Biotech, Inc. engages in the development of CAR-T cell therapy, a cancer immunotherapy for solid tumors using proprietary technology. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2023-06-28. The Cancer Immunotherapy Drug Discovery Business segment develops various gene-modified immuno-cell therapies for the treatment of solid tumors, mainly by combining PRIME technology, a platform technology, with therapeutic technologies targeting various antigens expressed by solid tumors. The firm establishes a hybrid business model with two business models: in-house drug discovery, in which the company takes the initiative in drug discovery, and joint pipeline, in which PRIME technology is licensed to other companies for drug development.

Intrinsic Value
92.15 JPY
Overvaluation 41%
Intrinsic Value
Price
N
What is Intrinsic Value?

See Also

What is Noile-Immune Biotech Inc's Other Liabilities?
Other Liabilities
5.2m JPY

Based on the financial report for Dec 31, 2023, Noile-Immune Biotech Inc's Other Liabilities amounts to 5.2m JPY.

What is Noile-Immune Biotech Inc's Other Liabilities growth rate?
Other Liabilities CAGR 3Y
0%

Over the last year, the Other Liabilities growth was 0%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.